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Abstract
There is considerable interest in developing nonpeptidic, small molecule α-helix mimetics to
disrupt α-helix-mediated protein-protein interactions. Herein, we report the design of a novel
pyrrolopyrimidine-based scaffold for such α-helix mimetics with increased conformational
rigidity. We also developed a facile solid phase synthetic route, which is amenable to divergent
synthesis of a large library. Using a fluorescence polarization-based assay, we identified cell
permeable, dual MDMX/MDM2 inhibitors, demonstrating that the designed molecules can act as
α-helix mimetics.
α-Helices represent one of the most common protein secondary structures and are involved
in various protein-protein interactions (PPIs). In many PPIs, short helical peptides play an
important role as a recognition motif, where side chains at i, i+3 or i+4, and i+7 positions
often become a critical determinant for PPIs (Figure 1A).1 Since α-helix-mediated PPIs are
involved in a wide array of cellular signaling pathways, inhibition of these interactions could
be promising therapeutic targets. While peptide- and peptidomimetic-based approaches have
shown successful applications to such targets,2 non-peptidic, small molecules have
advantages in terms of desirable bioavailability and cell permeability. Thus, there is
considerable interest in developing non-peptidic, small molecule α-helix mimetics that can
disrupt such PPIs. Hamilton and co-workers demonstrated that rationally designed terphenyl
1 and similar scaffolds can serve as α-helix mimetics (Figure 1B).1e Following their
pioneering work, a number of terphenyl-inspired structures have been reported.1e,3 While
some of these compounds have been shown to effectively disrupt certain PPIs, there are
several important issues associated with terphenyl-related structures, such as low aqueous
solubility, relatively flexible scaffold structure, and long synthetic routes. Herein, we report
design of a novel class of small molecule α-helix mimetics, development of a facile solid-
phase synthetic pathway, and a subsequent high-throughput screen, which led to the
identification of potent inhibitors that disrupt the interaction between p53 and MDMX/
MDM2.
On the basis of the Hamilton's terephthalamide 2 (Figure 1B),4 we designed a
pyrrolopyrimidine-based scaffold 3 (Figure 1C) with a hypothesis that the bicyclic ring in 3
could replace a pseudo-bicyclic structure formed by an intramolecular hydrogenbond in the
terephthalamide 2. Thus, the planar heterocyclic framework could provide a pre-organized
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structure with increased conformational rigidity. An energy-minimization study suggests
that three functional groups on R1, R2, and R3 of this scaffold can mimic the spatial
orientation of the side chains of i, i+3 or i+4, and i+7 amino acids in an α-helix (Figure
1A,C). In addition, the pyrrolopyrimidine template is expected to possess favorable physical
properties including water solubility and cell permeability, similar to its structurally related
purine and indole scaffolds, which are frequently used as privileged scaffolds in biology and
medicine.5
For the preparation of the designed compound 3, we developed a straightforward solid-phase
synthetic strategy by modifying a solution-phase synthesis of pyrrolopyrimidines (Scheme
1).6 First, we utilized peptoid synthesis conditions to introduce two functionalities (R1 and
R2). This efficient sub-monomer route7 includes bromoacetylation of amine group on Rink
amide MBHA resin, followed by displacement of the bromide with primary amines. After
repeating the same procedure, the resulting dimeric peptoids 6 were then coupled with 4,6-
dichloro-2-(methylthio)pyrimidine-5-carbaldehyde to afford aldehydes 7 in nearly
quantitative yield for 5 steps (Figure S1). Treatment of the aldehydes 7 with 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in DMF and MeOH provided pyrrolopyrimidines 8
through concomitant cyclization and dimethylamination.8 The thioether group was oxidized
by m-chloroperbenzoic acid (mCPBA) to give a sulfone, which was subsequently substituted
with various amines. The resin-bound tri-substituted bicyclic product 3 was cleaved with
trifluoroacetic acid (TFA). Crude products were analyzed for purity and identity by LC-MS.
To investigate efficiency of our synthetic pathway, a series of compounds 3 were
synthesized employing a variety of different amines. Synthesis with most tested amines
resulted in above 80% purity of the final products 3 as determined by LC-MS (Figure S1),
which is sufficiently pure for biological testing without further purification. The most
common by-product (< 5%) in the synthesis was 4-methoxy-substituted product (instead of
the N,N-dimethylamino group) obtained during the cyclization step. Those amines that
resulted in low purity (less than 70%) of final products were excluded in library synthesis.
Compared to relatively lengthy, linear synthesis of most terphenyl-related structures, our
synthetic route is simple and divergent and thus amenable to library synthesis. Notably,
since many structurally diverse primary amines are commercially available, a large
combinatorial library is readily accessible.
The efficacy of this scaffold as α-helix mimetics was assessed by monitoring its ability to
disrupt the p53-MDMX interaction. MDM2 and its homolog MDMX bind to the tumor
suppressor p53 and regulate its stability and activity. The interactions are mediated mainly
by three key residues (Phe19, Trp23, and Leu26) of p53 and the hydrophobic pocket in
MDMX and MDM2 (Figure 2A).2a,2b,9 Despite the similarity in the p53 recognition
surface of MDMX and MDM2, it proved to be challenging to identify MDMX inhibitors,
whereas a number of MDM2 inhibitors have been reported.10 Indeed, inhibitors developed
to target MDM2 show significantly less affinity to MDMX,9,11 and there is only one report
of MDMX-specific small molecule inhibitor.12 Given that MDMX is overexpressed in
many cancers and functions as a major regulator of p53 activity (both independently of and
synergistically with MDM2), the development of MDMX inhibitors (either MDMX-specific
or dual MDMX/MDM2 inhibitors) is highly desirable but still remains challenging.11,13
To search for such inhibitors, we constructed a 900-member library of compound 3
following Scheme 1. This was accomplished by a manual parallel synthesis (see Supporting
Information for details). Primary amines containing hydrophobic groups (aromatic or
aliphatic, shown in Figure S2) were selected with the intent of mimicking the side chains of
the three amino acids of p53 (Phe, Trp, and Leu). For quality control, 90 compounds (10%)
were randomly chosen from the library, and their purity and identity were verified by LC-
MS. As shown in Table S1, the average purity of the crude final products was 83%,
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indicating the robustness of the synthetic route. The library was used for screening without
further purification. A computational modeling showed that the scaffold could mimic
MDMX-bound p53 peptide (Figure 2B and Figure S3). The library molecules were screened
at ~40 μM concentration for the ability to displace a Rhodamine-labeled 15-mer p53 peptide
from MDMX protein by a fluorescence polarization (FP) assay (Figure S4, See Supporting
Information for details). From the screen, we identified two most active compounds, 3a and
3b (Figure 2C), which were resynthesized and purified by HPLC for further studies. The
overall yields for the synthesis of 3a and 3b were 26% and 40%, respectively, based on the
loading level of the resin (Figure S5). As expected, these compounds are highly soluble in
aqueous solution.14,15
We assessed the binding affinities of the selected compounds using the same FP-based
competitive assays. A 15-mer peptide derived from p53 and a known MDM2 inhibitor,
MI-63,16 were used as controls. As shown in Figure 3A, 3a and 3b effectively inhibited the
p53-MDMX binding with Ki of 0.62 μM and 0.45 μM, respectively, which were comparable
with that of a 15-mer p53 peptide (Ki = 0.8 μM). We then tested whether they could bind to
MDM2. Interestingly, they were found to inhibit the p53-MDM2 interaction as well with Ki
of 0.62 μM and 0.84 μM, respectively, similar to the binding affinities for MDMX (Figure
3B,C). These results suggest that the compounds act as dual inhibitors of MDMX- and
MDM2-p53 interactions.
Next we investigated the cellular activity of the inhibitors, since the compounds were
expected to be cell permeable as indicated above. To test this, we examined the effect of the
inhibitors on cellular levels of p53 and the cyclin-dependent kinase inhibitor p21, a major
transcriptional target of p53. Human lung cancer H460 cells expressing wild type p53 were
incubated with 3a, 3b, DMSO, or NC-1 (as a negative control), and cell lysates were
analyzed by Western blot to monitor p53 and p21 levels. Indeed, treatment of 3a and 3b led
to the increase of p53 and p21 levels in a dose-dependent manner, whereas DMSO and
NC-1 had no effects (Figure 3D and Figure S6). This result clearly demonstrates that the
compounds are not only cell-permeable, but also able to induce p53 level and activity in
cells.
Activation of p53 by the MDMX/MDM2 inhibitors would result in cell cycle arrest and
apoptosis. We examined the ability of the inhibitors to induce apoptosis by monitoring the
effect of 3a on caspase activity. H460 cells with wild type p53 and human lung cancer
H1299 cells with deleted p53 were exposed to DMSO, NC-1, 3a, or MI-63 (a positive
control) for 24 hours, and caspase activity was measured by Caspase-Glo 3/7 assay kit (see
Supporting Information). As shown in Figure 4, 3a and MI-63 induced caspase 3/7 activity
(about 3- and 5-fold, respectively) in H460 cells, while they had no effect on H1299 cells.
This result indicates that 3a triggers apoptosis through a p53-dependent pathway by binding
to MDMX/MDM2 and inhibiting their function toward p53.
While unnatural oligomer-based dual MDMX/MDM2 inhibitors such as β-peptides17 and
N-acylpolyamines18 have been reported, our compounds would have advantages as cell
permeable, small `drug-like' molecules. These dual-specific inhibitors should have a unique,
but overlapping, mechanism with current MDM2 inhibitors and thus could provide a
promising starting point for the development of a novel class of anti-cancer agents. Because
the inhibitors are initial hit compounds, further studies are needed. These include biological
evaluation of the inhibitors to elucidate the mode of mechanism as dual inhibitors,
investigation of the selectivity of the compounds among α-helix-recognizing proteins, and
X-ray and computational studies to better understand the molecular basis for the binding.
Experiments along these lines are underway.
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In summary, we have described the design of a pyrrolopyrimidine-based scaffold 3 as a
novel class of α-helix mimetics and the development of a facile solid-phase synthetic route
(Scheme 1). In addition, we have identified potent, dual inhibitors of MDMX- and MDM2-
p53 interactions through high-throughput screening, highlighting that they can serve as α-
helix mimetics (Figure 2, 3 and 4). Of note, our compounds have several important
advantages compared to most terphenyl-related structures, which include increased
conformational rigidity, improved aqueous solubility, excellent cell permeability and ease of
synthesis. Importantly, our divergent solid phase synthesis is amenable to the construction of
large libraries and subsequent high-throughput screening. Taken together, we believe that
our pyrrolopyrimidine-based scaffold along with the efficient solid phase synthesis will
serve as a useful tool to discover inhibitors of many α-helix-mediated PPIs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(A) α-Helix with i, i+4, and i+7 side chain positions. (B) α-Helix mimetics with terphenyl 1
and terephthalamide 2 scaffolds. (C) Pyrrolopyrimidine-based scaffold 3 and its energy-
minimized conformation (R1, R2, R3 = CH3).
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(A) Crystal structure of MDMX in complex with a p53 peptide (PDB entry: 2Z5S). (B)
Overlay of compound 3 (R1, R2, R3 = CH3) and an MDMX-bound p53 peptide. (C)
Structures of the active compounds (3a and 3b) and an inactive compound (NC-1).
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Inhibition curves for Rhodamine-labeled p53 peptide (SQETFSDLWKLLPEN-NH-
Rhodamine) binding to human MDMX (amino acids 1–137) (A) and human MDM2 (amino
acids 1–138) (B) by fluorescence polarization. (C) Ki values of inhibitors. aNot
determined. bUnlabeled 15-mer p53 peptide (SQETFSDLWKLLPEN).
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p53 activation by 3a. (A) Human lung cancer H460 cells expressing wild type p53 were
treated with DMSO or the indicated concentrations of 3a for 12 h. Lysates were subjected to
Western blot analysis. (B) H460 cells with wild type 53 and human lung cancer H1299 cells
with deleted p53 were exposed to DMSO, NC-1 (20 μM), 3a (20 μM) or MI-63 (20 μM) for
24 h. Caspase activity was analyzed by Caspase-Glo 3/7 assay kit (Promega).
Lee et al. Page 9















aReagents and conditions: (a) BrCH2CO2H, DIC, DMF, rt; (b) RNH2, DMF, rt; (c) 4,6-
dichloro-2-(methylthio)pyrimidine-5-carbaldehyde, DIEA/DMF, rt; (d) DBU/DMF-MeOH,
90°C; (e) mCPBA, NaHCO3, DCM, rt; (f) R3NH2, DIEA/NMP, 170°C; (g) TFA/DCM, rt.
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